Blockbuster
-
Shocking! Nearly $1 billion in sales, the blockbuster autoimmune drug Baricitinib’s compound patent and crystal form patent have both been declared invalid in China
DrugTimes will continue to follow up and report in a timely manner
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
